BioCardia, Inc. (BCDA)
BCDA Stock Price Chart
Explore BioCardia, Inc. interactive price chart. Choose custom timeframes to analyze BCDA price movements and trends.
BCDA Company Profile
Discover essential business fundamentals and corporate details for BioCardia, Inc. (BCDA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Nov 1996
Employees
17.00
Website
https://www.biocardia.comCEO
Peter A. Altman
Description
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
BCDA Financial Timeline
Browse a chronological timeline of BioCardia, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.19.
Earnings released on 15 May 2026
EPS came in at -$0.21 falling short of the estimated -$0.17 by -23.53%.
Earnings released on 24 Mar 2026
EPS came in at -$0.06 surpassing the estimated -$0.20 by +70.00%.
Earnings released on 12 Nov 2025
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%.
Earnings released on 11 Aug 2025
EPS came in at -$0.40 falling short of the estimated -$0.25 by -60.00%.
Earnings released on 14 May 2025
EPS came in at -$0.59 falling short of the estimated -$0.39 by -51.28%.
Earnings released on 26 Mar 2025
EPS came in at -$0.25 surpassing the estimated -$0.87 by +71.26%, while revenue for the quarter reached $25.00k , beating expectations by +11.11%.
Earnings released on 13 Nov 2024
EPS came in at -$0.61 surpassing the estimated -$1.19 by +48.74%, while revenue for the quarter reached $58.00k , beating expectations by +190.00%.
Earnings released on 13 Aug 2024
EPS came in at -$0.88 falling short of the estimated -$0.10 by -780.00%, while revenue for the quarter reached $3.00k , missing expectations by -94.00%.
Stock split effective on 30 May 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2024
EPS came in at -$1.35 surpassing the estimated -$3.00 by +55.00%, while revenue for the quarter reached $55.00k .
Earnings released on 27 Mar 2024
EPS came in at -$1.35 surpassing the estimated -$1.65 by +18.18%, while revenue for the quarter reached $13.00k , missing expectations by -85.56%.
Earnings released on 8 Nov 2023
EPS came in at -$1.80 matching the estimated -$1.80, while revenue for the quarter reached $357.00k , beating expectations by +296.67%.
Earnings released on 9 Aug 2023
EPS came in at -$2.55 falling short of the estimated -$2.25 by -13.33%, while revenue for the quarter reached $43.00k , missing expectations by -64.17%.
Earnings released on 10 May 2023
EPS came in at -$2.55 falling short of the estimated -$1.95 by -30.77%, while revenue for the quarter reached $64.00k , missing expectations by -81.18%.
Earnings released on 29 Mar 2023
EPS came in at -$2.40 surpassing the estimated -$2.70 by +11.11%, while revenue for the quarter reached $106.00k , beating expectations by +6.00%.
Earnings released on 9 Nov 2022
EPS came in at -$2.55 surpassing the estimated -$3.45 by +26.09%, while revenue for the quarter reached $212.00k , beating expectations by +87.61%.
Earnings released on 10 Aug 2022
EPS came in at -$2.10 surpassing the estimated -$4.20 by +50.00%, while revenue for the quarter reached $974.00k , beating expectations by +958.70%.
Earnings released on 11 May 2022
EPS came in at -$2.85 falling short of the estimated -$2.25 by -26.67%, while revenue for the quarter reached $60.00k , missing expectations by -68.42%.
Earnings released on 29 Mar 2022
EPS came in at -$3.15 matching the estimated -$3.15, while revenue for the quarter reached $79.00k , beating expectations by +141.22%.
Earnings released on 10 Nov 2021
EPS came in at -$2.40 falling short of the estimated -$0.21 by -1.04k%, while revenue for the quarter reached $821.00k .
Earnings released on 12 Aug 2021
EPS came in at -$3.00 surpassing the estimated -$3.15 by +4.76%, while revenue for the quarter reached $69.00k , meeting expectations.
BCDA Stock Performance
Access detailed BCDA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
